861 related articles for article (PubMed ID: 14969393)
21. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
[TBL] [Abstract][Full Text] [Related]
22. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
[TBL] [Abstract][Full Text] [Related]
23. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
24. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
[TBL] [Abstract][Full Text] [Related]
25. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
26. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
27. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
28. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway.
Kanematsu M; Yoshimura K; Takaoki M; Sato A
Bone; 2002 Apr; 30(4):553-8. PubMed ID: 11934645
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
30. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.
Fu Q; Jilka RL; Manolagas SC; O'Brien CA
J Biol Chem; 2002 Dec; 277(50):48868-75. PubMed ID: 12364326
[TBL] [Abstract][Full Text] [Related]
31. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer cells interact with osteoblasts to support osteoclast formation.
Thomas RJ; Guise TA; Yin JJ; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
Endocrinology; 1999 Oct; 140(10):4451-8. PubMed ID: 10499498
[TBL] [Abstract][Full Text] [Related]
33. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
Kim YH; Kim GS; Jeong-Hwa B
Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
[TBL] [Abstract][Full Text] [Related]
35. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
36. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
[TBL] [Abstract][Full Text] [Related]
38. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.
Locklin RM; Khosla S; Turner RT; Riggs BL
J Cell Biochem; 2003 May; 89(1):180-90. PubMed ID: 12682918
[TBL] [Abstract][Full Text] [Related]
39. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
40. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]